{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:47:04Z","timestamp":1779907624470,"version":"3.53.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bmcl.2026.130562","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T16:27:12Z","timestamp":1769790432000},"page":"130562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Nature-inspired chalcone-functionalized paracetamol derivatives as potential anticancer leads: synthesis, biological evaluation, apoptotic mechanisms, and in silico docking studies"],"prefix":"10.1016","volume":"134","author":[{"given":"Omaima F.","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana M.I.","family":"Morsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafaa S.","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raafat","family":"El-Awady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajjaj H.M.","family":"Abdu-Allah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etify A.","family":"Bakhite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bmcl.2026.130562_bb0005","doi-asserted-by":"crossref","first-page":"7762","DOI":"10.1021\/acs.chemrev.7b00020","article-title":"Chalcone: a privileged structure in medicinal chemistry","volume":"117","author":"Zhuang","year":"2017","journal-title":"Chem Rev"},{"issue":"32","key":"10.1016\/j.bmcl.2026.130562_bb0010","doi-asserted-by":"crossref","first-page":"27769","DOI":"10.1021\/acsomega.2c01779","article-title":"Synthesis of chalcones derivatives and their biological activities: a review","volume":"7","author":"Elkanzi","year":"2022","journal-title":"ACS Omega"},{"issue":"22","key":"10.1016\/j.bmcl.2026.130562_bb0015","doi-asserted-by":"crossref","first-page":"19194","DOI":"10.1021\/acsomega.3c01035","article-title":"Synthesis and pharmacological activities of chalcone and its derivatives bearing n-heterocyclic scaffolds: a review","volume":"8","author":"Mezgebe","year":"2023","journal-title":"ACS Omega"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130562_bb0020","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3390\/biom11060894","article-title":"Chalcone derivatives: role in anticancer therapy","volume":"11","author":"Ouyang","year":"2021","journal-title":"Biomolecules"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130562_bb0025","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.3390\/molecules28104009","article-title":"Anticancer activity of chalcones and its derivatives: review and in silico studies","volume":"28","author":"Leite","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2026.130562_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110297","article-title":"Chalcones: promising therapeutic agents targeting key players and signaling pathways regulating the hallmarks of cancer","volume":"369","author":"WalyEldeen","year":"2023","journal-title":"Chem Biol Interact"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130562_bb0035","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bmcl.2016.12.008","article-title":"De-sign, synthesis, biological evaluation, and molecular docking of chalcone derivatives as anti-inflammatory agents","volume":"27","author":"Li","year":"2017","journal-title":"Bio Med Chem Lett"},{"issue":"23","key":"10.1016\/j.bmcl.2026.130562_bb0040","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1021\/jm200946h","article-title":"Evaluation and discovery of novel synthetic chalcone de-rivatives as anti-inflammatory agents","volume":"54","author":"Wu","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130562_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103505","article-title":"Click chemistry synthesis, biological evaluation and docking study of some novel 2\u2032-hydroxychalcone-triazole hybrids as potent anti-inflammatory agents","volume":"95","author":"Boshra","year":"2020","journal-title":"Bioorg Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2026.130562_bb0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ebiom.2015.03.019","article-title":"Aspirin prevents colorectal cancer by normalizing EGFR expression","volume":"2","author":"Li","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bmcl.2026.130562_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105466","article-title":"Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties","volume":"117","author":"Srour","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2026.130562_or0005","doi-asserted-by":"crossref","unstructured":"(a)Cabrera, M.; Simoens, M.; Falchi, G.; Lavaggi, M. L.; Piro, O. E.; Castellano, E. E.; Vidal, A.; Azqueta, A.; Monge, A.; de Cer\u00e1in, A. L.; Sagrera, G.; Seoane, G.; Cerecetto, H.; Gonz\u00e1lez, M. Synthetic Chalcones, Flavanones, and Flavones as Antitumoral Agents: Biological Evaluation and Structure\u2013Activity Relationships. Bioorg Med Chem 2007; 15 (10): 3356\u20133367. doi: https:\/\/doi.org\/10.1016\/j.bmc.2007.03.031.","DOI":"10.1016\/j.bmc.2007.03.031"},{"key":"10.1016\/j.bmcl.2026.130562_rf0060","doi-asserted-by":"crossref","first-page":"1570385","DOI":"10.3389\/fphar.2025.1570385","article-title":"Pharmacological potential of natural chalcones: a recent studies and future perspective","volume":"16","author":"Adhikari","year":"2025","journal-title":"Front Pharmacol"},{"issue":"23","key":"10.1016\/j.bmcl.2026.130562_rf0065","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.3390\/molecules25235530","article-title":"Synthesis and biological evaluation of amino chalcone derivatives as antiproliferative agents","volume":"25","author":"Lu","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2026.130562_or0010","doi-asserted-by":"crossref","unstructured":"Um, Y.; Cho, S.; Ho Bum Woo; Yong Kee Kim; Kim, H.; Ham, J.; Kim, S.-N.; Chan Mug Ahn; Lee, S. Synthesis of curcumin mimics with multidrug resistance reversal activities. Bioorg Med Chem 2008; 16 (7): 3608\u20133615. doi: https:\/\/doi.org\/10.1016\/j.bmc.2008.02.012.","DOI":"10.1016\/j.bmc.2008.02.012"},{"key":"10.1016\/j.bmcl.2026.130562_rf0070","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.2147\/DDDT.S256756","article-title":"Novel HDAC\/tubulin dual inhibitor: design, synthesis and docking studies of \u03b1-phthalimido-chalcone hybrids as potential anticancer agents with apoptosis-inducing activity","volume":"14","author":"Mourad","year":"2020","journal-title":"Drug Des Dev Ther"},{"issue":"16","key":"10.1016\/j.bmcl.2026.130562_rf0075","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1016\/j.bmcl.2005.05.064","article-title":"Synthesis of novel curcumin mimics with asymmetrical units and their anti-angiogenic activity","volume":"15","author":"Woo","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130562_rf0080","first-page":"307","article-title":"Novel piperazine\u2013chalcone hybrids and related pyrazoline analogues targeting vegfr-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation","volume":"36","author":"Ahmed","year":"2020","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130562_rf0085","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1007\/s00044-011-9834-7","article-title":"Synthesis and biological evaluation of novel curcumin analogues as anti-inflammatory, anti-cancer and anti-oxidant agents","volume":"21","author":"Bandgar","year":"2011","journal-title":"Med Chem Res"},{"issue":"24","key":"10.1016\/j.bmcl.2026.130562_bb0080","doi-asserted-by":"crossref","first-page":"19043","DOI":"10.1039\/D5RA00834D","article-title":"Amide linked chalcone derivatives, a promising class of compounds with versatile biological effects","volume":"15","author":"Alshazly","year":"2025","journal-title":"RSC Adv"},{"issue":"13","key":"10.1016\/j.bmcl.2026.130562_bb0085","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2174\/1871520620999201124212840","article-title":"Chalcone scaffolds as anticancer drugs: a review on molecular insight in action of mechanisms and anticancer properties","volume":"21","author":"Shukla","year":"2021","journal-title":"Anti Cancer Agents Med Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130562_bb0090","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3390\/12040896","article-title":"4\u2019-acetamidochalcone derivatives as potential antinociceptive agents","volume":"12","author":"Campos-Buzzi","year":"2007","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2026.130562_bb0095","first-page":"1257","article-title":"Design, synthesis and characterization of novel paracetamol derivatives to target breast cancer","volume":"58B","author":"Ramanjaneyulu","year":"2019","journal-title":"Indian J Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130562_bb0100","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s11224-020-01707-5","article-title":"Synthesis, characterization, and anti-cancer activity of chalcone derivatives as-potent anaplastic lymphoma kinase inhibitors","volume":"32","author":"Lakshmanan","year":"2021","journal-title":"Struct Chem"},{"key":"10.1016\/j.bmcl.2026.130562_bb0105","doi-asserted-by":"crossref","unstructured":"Alam, M. M.; Alsenani, N. I.; Abdelhamid, A. A.; Ahmad, A.; Baothman, O. A.; Hosawi, S. A.; Altayeb, H.; Nadeem, M. S.; Ahmad, V.; Nazreen, S.; Elhenawy, A. A. New Paracetamol Hybrids as Anticancer and COX\u20102 Inhibitors: Synthesis, Biological Evaluation and Docking Studies. Arch Pharm 2023; 357(1): e2300340. doi: https:\/\/doi.org\/10.1002\/ardp.20230034022.","DOI":"10.1002\/ardp.202300340"},{"key":"10.1016\/j.bmcl.2026.130562_rf0115","doi-asserted-by":"crossref","first-page":"103149","DOI":"10.1016\/j.bioorg.2019.103149","article-title":"Synthesis, biological evaluation and mo-lecular docking studies of bis-chalcone derivatives as xanthine oxidase inhibitors and anticancer agents","volume":"91","author":"Burmaoglu","year":"2019","journal-title":"Bioorg Chem"},{"issue":"41","key":"10.1016\/j.bmcl.2026.130562_rf0120","doi-asserted-by":"crossref","first-page":"42061","DOI":"10.1021\/acsomega.4c04635","article-title":"Bis-Chalcones: recent reports of their diverse applications in biological and material sciences","volume":"9","author":"Siddiqui","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmcl.2026.130562_rf0125","doi-asserted-by":"crossref","first-page":"20220162","DOI":"10.1515\/hc-2022-0162","article-title":"Synthesis and conformational analysis of N-BOC-protected-3,5-bis(arylidene)-4-piperidone EF-24 analogs as anti-cancer agents","volume":"29","author":"Smith","year":"2023","journal-title":"Heterocycl Commun"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130562_bb0115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/106689690501300202","article-title":"Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma","volume":"13","author":"Raspollini","year":"2005","journal-title":"Int J Surg Pathol"},{"issue":"7","key":"10.1016\/j.bmcl.2026.130562_bb0120","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/sj.leu.2402534","article-title":"Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia","volume":"16","author":"Padr\u00f3","year":"2002","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130562_rf0140","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1572-0241.2002.05625.x","article-title":"Overexpression of Cyclooxygenase-2 cor-relates with advanced stages of colorectal cancer","volume":"97","author":"Zhang","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130562_rf0145","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/annonc\/mdf207","article-title":"Increased Cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients","volume":"13","author":"Ferrandina","year":"2002","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130562_rf0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/138955707780859431","article-title":"Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy","volume":"7","author":"Sarkar","year":"2007","journal-title":"Mini Rev Med Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130562_rf0155","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00001813-200202000-00003","article-title":"COX-2 Inhibitors in cancer treatment and prevention, a recent development","volume":"13","author":"Xu","year":"2002","journal-title":"Anti-Cancer Drugs"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130562_rf0160","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2174\/156800909790192437","article-title":"Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma","volume":"9","author":"Kao","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.bmcl.2026.130562_rf0165","doi-asserted-by":"crossref","first-page":"111693","DOI":"10.1016\/j.ejmech.2019.111693","article-title":"New oxadiazoles with selective COX-2 and EGFR dual inhibitory activity: design, synthesis, cytotoxicity evaluation and in silico studies","volume":"183","author":"El-Sayed","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130562_rf0170","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3390\/molecules27041158","article-title":"EGFR and COX-2 dual inhibitor: the design, synthesis, and biological evaluation of novel chalcones","volume":"27","author":"Musa","year":"2022","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130562_bb0140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/jpet.118.254359","article-title":"Inhibition of COX-2 and EGFR by Melafolone improves anti-PD-1 Therapy through vascular normalization and PD-l1 downregulation in lung cancer","volume":"368","author":"Tang","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"32","key":"10.1016\/j.bmcl.2026.130562_bb0145","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.18632\/oncotarget.5396","article-title":"Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma","volume":"6","author":"Rao","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmcl.2026.130562_bb0150","doi-asserted-by":"crossref","unstructured":"Valverde, A.; Pe\u00f1arando, J.; Ca\u00f1as, A.; L\u00f3pez-S\u00e1nchez, L. M.; Conde, F.; Hern\u00e1ndez, V.; Peralbo, E.; Chary L\u00f3pez-Pedrera; Haba-Rodr\u00edguez, J. D.; Aranda, E.; Rodr\u00edguez-Ariza, A. Simultaneous inhibition of EGFR\/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells. PLoS One 2015; 10 (6): e0131363\u2013e0131363. doi: https:\/\/doi.org\/10.1371\/journal.pone.0131363.","DOI":"10.1371\/journal.pone.0131363"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130562_bb0155","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1021\/acs.jmedchem.8b01755","article-title":"Discovery of novel quinoline\u2013chalcone derivatives as potent antitumor agents with microtubule polymerization inhibitory activity","volume":"62","author":"Li","year":"2018","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bmcl.2026.130562_rf0190","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0960-894X(98)00162-0","article-title":"Potent antimitotic and cell growth inhibitory properties of substituted chalcones","volume":"8","author":"Ducki","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130562_rf0195","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ejmech.2016.05.067","article-title":"Recent advances of cytotoxic chalconoids targeting tubulin polymerization: synthesis and bio-logical activity","volume":"121","author":"Mirzaei","year":"2016","journal-title":"Eur J Med Chem"},{"issue":"48","key":"10.1016\/j.bmcl.2026.130562_bb0165","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epi-dermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J Biol Chem"},{"issue":"45","key":"10.1016\/j.bmcl.2026.130562_bb0170","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2026.130562_bb0175","doi-asserted-by":"crossref","unstructured":"Wang, J. L.; Limburg, D.; Graneto, M. J.; Springer, J.; Hamper, J. R. B.; Liao, S.; Carter, J. Pawlitz, J. L.; Kurumbail, R. G.; Maziasz, T.; Talley, J. J.; Kiefer, J. R. The novel benzopyran class of selective cyclooxy-genase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life. Bioorg Med Chem Lett 2010; 20(23): 7159-7163. doi: https:\/\/doi.org\/10.1016\/j.bmcl.2010.07.054.","DOI":"10.1016\/j.bmcl.2010.07.054"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130562_bb0180","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.jmb.2014.02.005","article-title":"The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization","volume":"426","author":"Prota","year":"2014","journal-title":"J Mol Biol"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130562_bb0185","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2009","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmcl.2026.130562_bb0190","unstructured":"Syst\u00e8mes, D. BIOVIA Discovery Studio Visualizer. Dassault Sys-t\u00e8mes. In., vol. v24.1.0.23298. 2024 edn: San Diego; 2024. https:\/\/discover.3ds.com\/discovery-studio-visualizer-download."},{"issue":"11","key":"10.1016\/j.bmcl.2026.130562_bb0195","article-title":"UCSF ChimeraX: tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci A Publ Protein Soc"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:18:31Z","timestamp":1770470311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26000296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"alternative-id":["S0960894X26000296"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130562","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nature-inspired chalcone-functionalized paracetamol derivatives as potential anticancer leads: synthesis, biological evaluation, apoptotic mechanisms, and in silico docking studies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130562"}}